跳至主要内容
临床试验/NCT01056575
NCT01056575已完成1 期

An Open Label Balanced Study in Healthy Subjects to Evaluate the Potential for Cytochrome P 450 3A4 Induction by Oral OC000459 Using Oral Midazolam as a Probe

Oxagen Ltd1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2010年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Oxagen Ltd
入组人数
20
试验地点
1
主要终点
Ratio of exposure of midazolam and 4-hydroxymidazolam (without/with exposure to OC000459) as measured by plasma AUC0-t and Cmax for midazolam and its active metabolite 4-hydroxymidazolam.

研究概览

简要总结

This will be an open label, sequential study of midazolam (dose 5 mg orally) followed by midazolam (5 mg orally) given after dosing with OC000459 100 mg twice daily for 6.5 days. Twenty subjects will be included to ensure at least 16 subjects with analysable PK data. PK sampling for midazolam and 4-hydroxymidazolam plasma concentrations will continue for up to and including 24 hours after dosing with midazolam on both occasions.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Judged to be in good health at screening (blood tests, physical examination, medical history)

排除标准

  • Evidence of a clinically significant underlying medical condition that in the opinion of the Investigator would represent a risk to study participation.

研究组 & 干预措施

OC000459

Experimental

干预措施: OC000459 (Drug)

结局指标

主要结局

Ratio of exposure of midazolam and 4-hydroxymidazolam (without/with exposure to OC000459) as measured by plasma AUC0-t and Cmax for midazolam and its active metabolite 4-hydroxymidazolam.

时间窗: 6.5 days

次要结局

  • Additional PK parameters of midazolam and its active metabolite 4-hydroxymidazolam(6.5 days)
  • Safety and tolerability of OC000459(6.5 days)

研究者

发起方
Oxagen Ltd
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

Study to Evaluate the Potential for Interaction... | 临床试验